DWP 220
Alternative Names: DWP-220Latest Information Update: 25 Oct 2022
At a glance
- Originator Daewoong Pharmaceutical
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis
Most Recent Events
- 20 Oct 2022 Discontinued for Fibrosis in South Korea (unspecified route) (Daewoong pipeline, October 2022)
- 16 Dec 2021 Early research in Fibrosis in South Korea (unspecified route) (Daewoong Pharmaceutical pipeline December 2021)